Osteoprotegerin Kit ELISA

N° du produit ABIN456063

Détail du produit Osteoprotegerin Kit ELISA

Antigène: Osteoprotegerin (TNFRSF11B) (Tumor Necrosis Factor Receptor Superfamily, Member 11b (TNFRSF11B))

Reactivité: Souris

Méthode de détection: Colorimetric

Type de méthode: Sandwich ELISA

Gamme de detection: 7.8-500 pg/mL

Seuil minimal de détection: 7.8 pg/mL

Application: ELISA

Fonction: This immunoassay kit allows for the in vitro quantitative determination of mouse Osteoprotegerin, OPG concentrations in serum, plasma and other biological fluids.

Type d'échantillon: Plasma, Serum

Analytical Method: Quantitative

Specificité: This assay recognizes recombinant and natural mouse OPG.

Réactivité croisée (Details): No significant cross-reactivity or interference was observed.

Sensibilité: < 3.9 pg/mL
The sensitivity of this assay, or Lower Limit of Detection (LLD) was defined as the lowest detectable concentration that could be differentiated from zero.

Attributs du produit: Mus musculus,Mouse,Tumor necrosis factor receptor superfamily member 11B,Osteoclastogenesis inhibitory factor,Osteoprotegerin,Tnfrsf11b,Ocif,Opg

Information d'application

Volume d'échantillon: 100 μL

Plaque: Pre-coated

Protocole: The microtiter plate provided in this kit has been pre-coated with an antibody specific to OPG. Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated polyclonal antibody preparation specific for OPG and Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. Then a TMB substrate solution is added to each well. Only those wells that contain OPG, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of a sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The concentration of OPG in the samples is then determined by comparing the O.D. of the samples to the standard curve. 2

Restrictions: For Research Use only

Stockage

Stock: 4 °C/-20 °C

Stockage commentaire: The Standard, Detection Reagent A, Detection Reagent B and the 96-well strip plate should be stored at -20 °C upon being received. The other reagents can be stored at 4 °C.

Détail du antigène

Antigène: Osteoprotegerin (TNFRSF11B) (Tumor Necrosis Factor Receptor Superfamily, Member 11b (TNFRSF11B))

Autre désignation: Tnfrsf11b (TNFRSF11B Produits)

Synonymes: CD254 Kit ELISA, ODF Kit ELISA, OPGL Kit ELISA, OPTB2 Kit ELISA, RANKL Kit ELISA, TRANCE Kit ELISA, hRANKL2 Kit ELISA, sOdf Kit ELISA, OCIF Kit ELISA, OPG Kit ELISA, TR1 Kit ELISA, Opg Kit ELISA, ocif Kit ELISA, opg Kit ELISA, tr1 Kit ELISA, TNF superfamily member 11 Kit ELISA, TNF receptor superfamily member 11b Kit ELISA, tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) Kit ELISA, TNF receptor superfamily member 11B Kit ELISA, tumor necrosis factor receptor superfamily member 11b S homeolog Kit ELISA, tumor necrosis factor receptor superfamily, member 11b Kit ELISA, TNFSF11 Kit ELISA, TNFRSF11B Kit ELISA, Tnfrsf11b Kit ELISA, tnfrsf11b.S Kit ELISA

Classe de substances: Chemical

Sujet: Osteoprotegerin, also known as osteoclastogenesis inhibitory factor (OCIF), is a cytokine and a member of the tumor necrosis factor (TNF) receptor superfamily. It is a basic glycoprotein comprising 401 amino acid residues arranged into 7 structural domains. It is found as either a 60 kDa monomer or 120 kDa dimer linked by disulfide bonds.Osteoprotegerin inhibits the differentiation of macrophages into osteoclasts and also regulates the resorption of osteoclasts in vitro and in vivo. Osteoprotegerin is a RANK homolog, and works by binding to RANK ligand on osteoblast/stromal cells, thus blocking the RANK-RANK ligand interaction between osteoblast/stromal cells and osteoclast precursors. This has the effect of inhibiting the differentiation of the osteoclast precursor into a mature osteoclast. Recombinant human osteoprotegerin specifically acts on bone, increasing bone mineral density and bone volume. Osteoprotegerin has been used experimentally to decrease bone resorption in women with postmenopausal osteoporosis and in patients with lytic bone metastases. Osteoprotegerin production is stimulated in vivo by the female sex hormone estrogen,as well as the experimental osteoporosis drug, strontium ranelate.